FDA to hold joint meeting to evaluate Merck's OTC use of Mevacor to help lower cholesterol and prevent heart attack.
In the Oct. 23 Federal Register, the FDA announced a joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees to be held in Washington, D.C., on Dec. 13. The committees will evaluate data submitted by Merck & Co to support the over-the-counter use of Mevacor (lovastatin) 20 mg a day to help lower cholesterol, which may prevent a first heart attack. For background material, visit
